Novel Antibacterial Agents

The need for novel antibiotics is well understood by anyone familiar to the field. We have discovered a novel class of antibiotics that are structurally unique from all previously known antibiotics and appear to operate via a distinctive mode of action. As a result, these new agents appear to represent significant promise as new treatments for the emerging problem of MDR infections. In less than 5 years, PolyMedix has translated one of these novel molecules from discovery to Phase 1a human clinical trials with a planned indication to broadly treat Staphylococcal infections including methicillin-resistant S. aureus. This proposal describes our efforts to develop lead compounds against those pathogens most relevant to military personnel with a specific focus on Acinetobacter and P. aeruginosa.